Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

DISEASE CHARACTERISTICS: * Histologically proven solid tumor or lymphoma that is not curable by surgery, radiotherapy, or standard chemotherapy, or for which no curative therapy exists * Prostate cancer patients must have the following: * Tumor progression following blockade of both testicular and adrenal androgens * Serum testosterone in the castrate range (less than 20 ng/mL) * At least 3 months since prior suramin therapy * At least 4 weeks since prior flutamide or other antiandrogen medication and no evidence of response to treatment * Luprolide should continue if no prior orchiectomy * No prior or concurrent brain metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0 or 1 Life expectancy: * At least 3 months Hematopoietic: * WBC at least 3,500/mm\^3 OR * Granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 8 g/dL Hepatic: * Hepatitis B surface antigen negative * PT no greater than 14 seconds * PTT no greater than 35 seconds * Bilirubin no greater than 1.5 mg/dL unless due to Gilbert's disease * SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN) * Alkaline phosphatase no greater than 2.5 times ULN * Albumin at least 2.5 g/dL Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 50 mL/min * Corrected calcium at least 8.0 mg/dL, but no greater than 10.7 mg/dL Cardiovascular: * No prior myocardial infarction, coronary artery disease (CAD), congestive heart failure, second or third degree AV block, or cardiac arrhythmias requiring treatment * No evidence of CAD on EKG Pulmonary: * FEV1-1 at least 70% predicted * DLCO at least 60% predicted Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * At least 1 week since active infection requiring antibiotics * No other medical or psychiatric condition that would preclude study * No prior or concurrent seizure disorders controlled with medication PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior interleukin-2 * At least 4 weeks since other prior biologic therapy for solid tumors or lymphomas Chemotherapy: * See Disease Characteristics * At least 4 weeks since prior bryostatin 1 * At least 4 weeks since other prior chemotherapy for solid tumors or lymphomas Endocrine therapy: * See Disease Characteristics * At least 4 weeks since other prior endocrine therapy for solid tumors or lymphomas * No absolute requirement for corticosteroids Radiotherapy: * See Disease Characteristics * At least 4 weeks since prior radiotherapy for solid tumors or lymphomas Surgery: * See Disease Characteristics * At least 4 weeks since prior surgery for solid tumors or lymphomas Other: * No absolute requirement for nonsteroidal anti-inflammatory drugs or H2 blockers